We have worked together to map out strategies for raising the impact factor. I should say that we have never tried to artificially inflate this journal's impact factor. Our plans going forward are aimed at attracting original manuscripts that are highly innovative, that affect our thinking about the biology or therapeutic design. We intend to more actively highlight the most valuable insights gained from the original research that we publish. We remain committed to the translational goals that include publishing up to early phase clinical trials, bedside-to-bench reports, and reviews that highlight the continuum from basic science to patient care. Fundamental basic research on any area of cancer is also very important, as is that investigator-driven NIH R01 grant.
Expect to hear from us. We are planning to engage you in the future of this journal as it continues on its journey of improvement. We are interested in hearing from you directly through Letters to the Editor, whether it is about the plight of biomedical research, the obstacles we are all facing, your vision of the future of cancer care or personalized therapy. We welcome your contributions, whether it is original papers on the tumor microenvironment, tumor heterogeneity and stem cells, molecular imaging, new biomarkers, developmental therapeutics, drug resistance, crosstalk, or feedback loops. Paul will be working with me in actively soliciting original contributions and commentaries and will be working with us to assist our Reviews Editor Dr Gen Sheng Wu in the solicitation of reviews. We are all committed and reaffirm our commitment to ultra-rapid turnaround time of submissions. Feel free to send in your best papers that should be published in the near future. I, like many of you, run a basic and translational research lab with limited resources. I have served on NIH study sections for 15 years, and have been funded for my entire career. I know very well what it means when your best most innovative work is held up in multiple revisions for two years while the careers of your trainees and the fate of your grants are in the balance, not to mention the ultimate impact due to the passage of time. I believe Cancer Biology & Therapy can make a difference for your high impact work and we are committed to doing our part.
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